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Abstract: The ADAR proteins deaminate adenosine to inosine in double-stranded RNA 
which is one of the most abundant modifications present in mammalian RNA. Inosine can 
have a profound effect on the RNAs that are edited, not only changing the base-pairing 
properties, but can also result in recoding, as inosine behaves as if it were guanosine.  
In mammals there are three ADAR proteins and two ADAR-related proteins (ADAD) 
expressed. All have a very similar modular structure; however, both their expression and 
biological function differ significantly. Only two of the ADAR proteins have enzymatic 
activity. However, both ADAR and ADAD proteins possess the ability to bind double-strand 
RNA. Mutations in ADARs have been associated with many diseases ranging from cancer, 
innate immunity to neurological disorders. Here, we will discuss in detail the domain 
structure of mammalian ADARs, the effects of RNA editing, and the role of ADARs in 
human diseases. 
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1. Introduction 
RNAs in the cell are rarely found without proteins attached; instead they are present as 
ribonucleoproteins (RNPs) complexes that are formed co-transcriptionally. RNA can also undergo a 
large number of modifications; over 100 have been described to date and this number is likely to be 
underestimated [1]. Since the nucleotide composition of a given RNA determines its chemical and 
structural proprieties, base modifications can either increase or decrease the stability of the RNA 
structures. It can also influence the repertoire of proteins binding to RNA and consequently have 
dramatic effects that can lead to disease. In this chapter we will focus on one of the most widespread and 
abundant type of post-transcriptional RNA modification/editing; enzymatic deamination of adenosine 
residues (A) to inosine (I) within double-stranded RNAs (dsRNAs) which is catalyzed by the ADAR 
(adenine deaminase acting on RNA) family of proteins. 
2. RNA Editing 
The term RNA editing was coined by Rob Benne when he discovered that the mitochondrial cytochrome 
oxidase subunit II gene from the trypanosomes species Trypanosoma brucei and Crithidia fasciculata 
contain a frameshift at amino acid 170 [2]. Four nucleotides are inserted at the frameshift position that 
are not encoded in the DNA and this restores the reading frame. This finding was subsequently confirmed 
by others who demonstrated that RNA editing was essential for the generation of functional mitochondrial 
proteins in trypanosomes [3]. In 1987, the field of mammalian RNA editing was established when that 
year the first papers were published. The initial publications were by the groups of Weintraub and Melton 
who discovered an activity that unwound RNA duplexes [4,5]. Initially this activity was described as an 
RNA helicase however it was subsequently shown to be a deaminase encoded by ADAR [6]. The second 
breakthrough came from the laboratory of James Scott who found that a tissue-specific RNA 
modification results in two distinct proteins being generated from the same primary transcript [7]. The 
conversion of cytosine (C) into uracil (U) by deamination generates a stop codon in the transcript 
encoding apolipoprotein B (apoB) is catalyzed by the apolipoprotein B mRNA-editing enzyme catalytic 
polypeptide 1 (APOBEC1). Thus, in the context of the time, the initial assumption was that the function 
of RNA editing was to restore an open reading frame or to generate alternative isoforms of the encoded 
protein. Therefore, it was considered to be distinct from RNA modification that modifies RNA without 
creating protein diversity. However, in hindsight, are RNA editing and RNA modification two sides of 
the same coin?  
The cytidine deaminase (CDA) super family of enzymes includes both the ADAR and the APOBEC 
family of proteins as well as adenosine deaminase acting on the tRNA (ADAT) family. These enzymes 
catalyze deamination and their catalytic domain is evolutionarily conserved [8]. Following the 
identification of ADAR1 [9–11] the search for other ADAR-like genes began and this led to the 
discovery of ADAR2 (also known as ADARB1) [12–14]. The brain-specific ADAR3 (also known as 
ADARB2) was also identified based on its homology with ADAR2 [15]. A screen for genes that encode 
RNA binding proteins led to the identification of the testis nuclear RNA binding protein (TENR) [16]. 
TENR is testis-specific and found to contain a catalytically-inactive deaminase domain [16]. Due to the 
annotation of a second testis-specific gene encoding an adenosine deaminase domain containing protein 
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(ADAD2), TENR has been renamed to ADAD1. Thus, there are three ADAR genes and two ADAD 
genes which are ADAR related in mammals: ADAR1 and ADAR2 are catalytically active, whereas 
ADAR3, ADAD1, and ADAD2 are not enzymatically active, but are dsRNA binding proteins (Figure 1).  
3. Domain Organization and Structure of ADAR Enzymes 
ADARs are modular proteins containing similar functional domains. All have at their N-terminus 
double-stranded RNA binding domains (dsRBDs), which make direct contacts with the dsRNA 
substrates whereas the catalytic deaminase domain is located at the C-terminus (Figure 1). Some have 
distinct domains not present in other family members. 
 
Figure 1. Domain organization of ADAR and ADAD proteins expressed in Homo sapiens. 
All of the proteins contain N-terminal dsRBDs and C-terminal deaminase domains. An 
arginine rich (R) region is present at the N-terminus of ADAR3. There are two isoforms of 
hADAR1, ADAR1 p110 and ADAR1p150, both of which contain a Z-DNA binding 
domains (ZBD) at the N-terminal.  
The ADAR1 gene was mapped to the q21.1–21.2 locus on chromosome one in humans [17]. It extends 
~40 kb and contains 17 exons [18]. There are two different isoforms of ADAR1; a 150 kDa protein 
(ADAR1 p150) that is induced by interferon (IFN) and a 110 kDa protein (ADAR1 p110) that is 
constitutively expressed [19]. The two isoforms have distinct translation initiation sites so that ADAR1p150 
starts translation in exon 1A (AUG1) whilst the ADAR1p110 protein initiates from exon two  
(AUG296) [19,20]. The generation of different ADAR1 isoforms is due to the alternative splicing of the 
exon one. An IFN-inducible promoter located in exon 1A contains a 12-bp IFN-stimulated response 
element (ISRE), thereby generating the transcript coding for the longer ADAR1p150 isoform [21]. 
However, transcripts encoding ADAR1p110 are generated from multiple promoters located within exon 
1B, 1C and exon two [21,22]. As neither exon 1B nor exon 1C contain translation initiation sites, 
translation starts at the AUG296 codon within exon two. Additional alternative splicing events have 
been identified within exon 7 to generate variants that contain either exon 7a or 7b [20]. Exon 7b is 
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missing 26 amino acids that are present in exon 7a [20]. Furthermore, exon 7b is associated with 
ADAR1p150 transcripts whereas exon 7a is present in the constitutively-expressed ADAR1p110 
transcripts [23]. 
A unique feature of ADAR1 when compared to other members of the ADAR family, is the presence 
of Z-DNA binding domains (ZBDs) at the N-terminus. The Z-alpha (Zα) domain is exclusive to the 
ADAR1p150 isoform whereas both ADAR1p150 and ADAR1p110 contain a Zβ domain [24]. The 
ZBDs bind DNA/RNA that is in a left handed conformation [25]; however, only the Zα domain has  
Z-DNA/RNA binding capacity [26]. Although the functional significance of the ZBDs in ADAR1 is 
unclear, all proteins containing Zα domains have been implicated in the type I IFN response  
pathway [27]. Furthermore, the Zα domain is essential for the localization of ADAR1p150 to 
cytoplasmic stress granules following activation of type I IFN-induced stress [28]. 
In vitro analysis of recombinant ADAR3 demonstrated that it can bind both dsRNA and ssRNA [29]. 
Site-directed mutagenesis of ADAR3 revealed that it binds ssRNA via a unique arginine/lysine rich 
domain (R-domain) located in the N-terminus. This R-domain is important for determining the 
subcellular localization of ADAR3 and acts as a nuclear localization signal (NLS) [30]. The importin 
alpha-1 factor, KPNA2 recognizes and interacts with this R-domain to promote the nuclear import  
of ADAR3. 
4. dsRNA Binding Domains of ADARs 
All proteins that bind to dsRNA contain an evolutionarily-conserved 65-68 amino acid homologous 
sequence that is known as dsRBD [31]. It was originally identified in Drosophila Staufen and Xenopus 
Xlrbpa proteins [31]. Nuclear magnetic resonance (NMR) studies have characterized the canonical 
dsRBD fold with a topology of: α-helix 1, β-strand 1, β-strand 2, β strand 3, and α-helix 2 (αβββα) [32–34]. 
The two α-helices lie on one side of the three-stranded anti-parallel β-sheet creating a hydrophobic core 
that makes contact with the RNA substrate (Figure 2a) [35]. In particular, the N-terminal tip of the  
α-helix 2 plays a significant role in the interactions between the dsRBD and the dsRNA substrate. This 
particular region is part of the dsRBD consensus sequence and consists of a cluster of lysines, KKXXK 
(where X is any amino acid) [31]. In vitro mutagenesis studies of these lysine residues have demonstrated 
their importance for both the binding and editing function of ADARs [36–38]. 
NMR chemical shift perturbation studies of ADAR2 bound to a 71nt hairpin RNA encoding the R/G 
editing site of the Gria2 transcript revealed that dsRBD1 recognizes a conserved pentaloop whereas the 
dsRBD2 binds two bulges close to the editing site (Figure 2) [36,37]. Stefl and colleagues also 
demonstrate that the orientation of α-helix 1 is different between the two dsRBD and this affects the 
interactions with α-helix 2 in the respective dsRBD. Additionally, the conformation of the β1-β2 loop 
also differs between the two dsRBDs [36,37]. These results suggest that dsRNA substrate recognition 
by ADARs is achieved through their dsRBDs via recognition of a specific structure.  
Although all dsRBDs have a consensus sequence that is essential for dsRNA binding, each protein 
differs functionally and this is reflected in their RNA binding specificity. Liu and colleagues investigated 
whether the dsRBDs contributed to the activity of ADAR1 [39]. Chimeric proteins were created whereby 
the dsRBDs of ADAR1 were substituted with those of PKR. Analysis of the recombinant PKR-ADAR1 
chimera revealed that the editing activity was significantly impaired compared to wild-type ADAR1 [39]. 
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Furthermore, small inhibitory RNA substrates that bind PKR were also able to inhibit the editing activity 
of the PKR-ADAR1 chimera. These results demonstrate that the dsRBDs play a role in substrate 
specificity which in turn influences the function of ADARs. 
Differences also exist between the dsRBDs amongst the ADAR proteins. Mutagenic analysis of 
ADAR1 revealed that deletion of dsRBD2 has no effect on the editing activity of the enzyme whereas 
the deletion of dsRBD1 or dsRBD3 significantly reduces the its editing activity [40]. Interestingly, the 
two dsRBDs of ADAR2 align to dsRBD1 and dsRBD3 of ADAR1 [13]. Analysis of the two dsRBDs in 
ADAR2 demonstrated that dsRBD2 is required for editing of all substrates whereas dsRBD1 is only 
required for editing of a specific subset of substrates [38]. Furthermore, point mutations in dsRBD2 only 
affected editing of some of its substrates suggesting that it uses different amino acids to interact with 
different RNAs [36,37]. Together, these studies demonstrate that each of the dsRBDs recognize specific 
elements in the RNA substrate.  
 
Figure 2. Structural information of ADAR enzymes. (A) NMR structure of the dsRBD1 and 
dsRBD2 of hADAR2 (blue) in complex with the RG stem loop RNA target [37]. The specific 
adenosine that is deaminated in the catalytic reaction is highlighted in red. In grey is shown 
where the deaminase domain is likely positioning during the reaction. PDB file: 2L3J.  
(B) Crystal structure of the catalytic domain of hADAR2 [41], secondary structures are 
colored from yellow (N-terminus) to red (C-terminus). The Zinc ion and inositol 
hexakisphosphate molecule (IP6) cofactor are highlighted and colored in blue. PDB file: 1ZY7. 
5. The Catalytic Deaminase Domain 
The structure of the deaminase domain of hADAR2 has been solved by X-ray crystallography [41]. 
This C-terminal 45 kDa domain comprises of 400 residues which form a globular structure similar to the 
deaminase domain found in other CDA family members [42–45]. This core deaminase motif consists of 
two α-helices (α2 and α5) and four β-strands (β1, β2, β5, and β8) [41]. Additionally, the active site  
of this deaminase domain contains one zinc ion and one molecule of inositol hexakisphosphate (IP6)  
(Figure 2b).  
Biomolecules 2015, 5 2343 
 
 
Hydrolytic deamination catalyzed by ADARs uses a nucleophile comprised of a zinc atom (Zn2+) and 
a water molecule (H20). The crystal structure of ADAR2 revealed that the Zn
2+ atom is coordinated by 
two cysteines (C451 and C516) and a histidine (H394) [41]. Mutagenic analysis of the predicted Zn2+ 
coordinating residues in ADAR1; His 910, Cys 966, and Cys1036 resulted in complete loss of ADAR1 
activity demonstrating the essential role of Zn2+ in the catalysis [40]. A highly conserved glutamate 
residue (E) participates in the proton transfer cascade during deamination. In ADAR2 the glutamate 
residue (E396) is the acceptor of a proton from the nucleophilic water molecule bound by the zinc atom. 
This produces a highly-reactive negatively-charged zinc-hydroxide that reacts with carbon 6 (C6) of the 
adenosine occupying the active site. The removal of a proton from the zinc-hydroxide ion results in the 
displacement of ammonia (NH3) during the reaction. Replacing this glutamate residue with an alanine 
results in a loss of catalytic activity of ADAR2 [40]. 
A unique feature identified in the crystal structure of ADAR2 is the presence of an IP6 molecule in 
the core site of the deaminase domain [41]. In the cell, the cleavage of phosphatidylinositol biphosphate 
by phospholipase C (PLC) generates IP3 which is subsequently phosphorylated to produce IP6 [46].  
In ADAR2, the IP6 molecule is located in a basic cavity where it is tightly associated to conserved 
residues via hydrogen bonds and it is thought to contribute to the folding of the protein [41]. Macbeth 
and colleagues demonstrate that IP6 is an essential ADAR2 cofactor as S. cerevisae that are unable to 
synthesize IP6 cannot express catalytically-active ADAR2 [41]. Another study also demonstrated the 
importance of IP6 for ADAR2 activity. Schmauss and colleagues were investigating the regulation of 
the serotonin receptor (5-HT2C) mRNA and observed that an increase in serotonin (5-HT) levels resulted 
in increased editing of 5-HT2C pre-mRNA [47]. High levels of 5-HT led to the induction of PLC and the 
subsequent production of IP6 which could contribute to the production of ADAR2 which edits the  
5-HT2C pre-mRNA. Editing of the 5-HT2C pre-mRNA decreases the production of 5-HT implicating that 
IP6 is a rate limiting factor in this negative feedback regulatory loop [47]. 
As the edited base lies within the deep and narrow major groove of the A-form RNA helix, it was 
proposed that the ADARs use a base-flipping mechanism to facilitate the deaminase domain access to 
the adenine base [48]. The mechanism of recognition of the edited base by ADAR1 and ADAR2 is very 
similar however ADAR1 is more dependent on the presence of N7 in the edited base [49]. Structural 
studies of the ADAR2 active site revealed that the architecture of the zinc ion and its coordinating 
residues would require a conformational change in the RNA before deamination. Stephens and 
colleagues used a fluorescent RNA probe that is quenched when the RNA helical duplex is naturally 
stacked and observed a significant increase in fluorescence emission from an RNA substrate bound  
at the active site of ADAR2 indicating that ADAR2 causes a conformational change at the editing  
site [50,51]. Another study used molecular dynamics simulations to investigate base-flipping at two sites 
within the Gria2 transcript, at an edited and a non-edited site [52]. They found that the adenosine base 
at the editing site is more flexible and is inclined to move out into the minor groove. Beal and colleagues 
who were investigating the protein-RNA conformational changes that occur during deamination, found 
that nucleotides near the editing site on the opposite strand of the RNA become hypersensitive to 
hydrolytic cleavage after binding by the dsRBD of ADAR2 [53], indicating that RNA binding by ADAR 
changes the conformation of the RNA. In the same study, a tryptophan fluorescent probe was used to 
demonstrate conformational changes in the deaminase domain of ADAR2 in the presence of an  
RNA substrate. 
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Despite being isolated and characterized over 20 years ago, there is currently no structural information 
for a full-length ADAR containing both the dsRBDs and the deaminase domains. Nor is there any  
co-crystal of an ADAR protein with its dsRNA substrate. This is due to the modular nature of these 
enzymes which is a source of flexibility that makes in vitro studies and crystallization experiments more 
challenging. Another open question in the field is the role of dimerization of ADARs in the function of 
this family of enzymes. The ADAR proteins were shown to form dimers in vitro and in vivo [54–56]. 
However, it is still controversial whether the dimerization is essential for the activity [57] and whether 
it occurs in a RNA-dependent [54,55] or independent manner [58]. 
6. The Two Types of A-to-I RNA Editing 
A-to-I editing by ADARs can be classified into two types: site-specific and promiscuous editing.  
Site-specific editing occurs within short, imperfectly-paired regions of dsRNA that can result in recoding 
of open reading frames to generate proteins with altered functions. High levels of site-specific RNA 
editing are found in transcripts that are expressed in the CNS. Since inosines prefer to base-pair with 
cytosine (C), a guanosine residue is inserted when cDNA is generated. Inosine is read as if it were 
guanosine by the translational machinery thus recoding the mRNA. 
The second type of editing occurs within long dsRNA structures (>100 bp) that are deaminated at 
multiple sites. It has been demonstrated that up to 50% of the adenosine residues within these long 
dsRNAs can be deaminated so therefore this type of editing is referred to as hyper or promiscuous  
editing [48,59]. The deamination of an adenosine within an A-U base pair duplex produces the less stable 
I-U wobble pair, while deamination within A-C mismatches produces the more stable I-C pairs. These 
editing events are found within RNA duplex structures formed by inverted Alus and other repetitive 
elements within the non-coding regions of transcripts such as introns and 3ʹUTR regions as well as within 
transcribed intragenic regions [60–65]. The presence of A-to-I modifications in transcripts encoding Alu 
elements and other hyperedited transcripts regulate the structure and stability of the dsRNAs and inosine-
containing dsRNAs have been shown to play an essential role in regulating the innate immune  
response [66,67]. This type of editing will be discussed later. 
7. RNA Editing Resulting in Recoding 
When compared to mammals invertebrates have a significantly higher level of editing that results in 
recoding (for review, see [68]). In octopus, editing of transcripts encoding a potassium channel has been 
shown to vary depending on the location of the species, being highly edited in cold waters, whereas 
tropical water species are mostly unedited [69]. This elegant experiment suggests that RNA editing can 
respond to environmental queues. 
The transcript encoding one of the α-amino-3-hydroxy-5-methylisoxasole-4propionate (AMPA) 
receptor subunit is the best studied mammalian site-specific editing event [70,71]. The AMPA receptor 
is a glutamate-gated ion channel that mediate fast synaptic transmission at excitatory synapses which are 
important for neuronal development, long term potentiation and synaptic plasticity. AMPA receptors are 
activated by L-glutamine which triggers an influx of calcium (Ca2+) into the neuron. The Ca2+ 
permeability of the AMAP receptors is dependent on the tetrameric composition of the subunit of the 
glutamate receptor [72]. AMPA receptors containing the glutamate receptor 2 (GRIA2) subunit exhibit 
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lower Ca2+ permeability compared to those without it and this is due to the presence of single amino acid 
residue, arginine (R) in the pore of the channel [73]. When comparing cDNA and genomic sequences 
encoding the GRIA2 subunit, it was found that the R codon (CGG) in the cDNA was a glutamine (Q) 
codon (CAG) in the genomic sequence [70]. ADAR2 is the enzyme that catalyzes this critical site 
specific editing event at this Q/R site [74]. This editing event also regulates the heterotetrameric 
assembly of the AMPA receptors by retaining the GRIA2 subunits within the endoplasmic reticulum 
therefore increasing the time required for it to be transported to the synaptic surface [75,76] Editing at 
this Q/R site is highly efficient >99% in the CNS and it dictates the Ca2+ permeability of the AMPA 
receptor. It is therefore is a key determinant in neuronal Ca2+ homeostasis, as the edited isoform, GRIA2 
(R), is impermeable to Ca2+. 
The early onset epileptic seizures and premature death of both Adar2 null mice and mice heterozygous 
for an uneditable GRIA2 allele demonstrated the physiological importance of this editing event [77,78]. 
The Adar2 null phenotype is rescued by generating a transgenic mouse containing the edited GRIA2 
allele [71]. In addition to the Q/R site, the GRIA2 transcript is also edited at the R/G site [79]. The 
transcript encoding the GRIK2 subunit of the high affinity kainite (KA) receptor is edited at the Q/R site 
in transmembrane segment 1 (TM1) and also at the I/V and Y/C sites in TM2 [80]. Editing at these 
positions affects the Ca2+ permeability of the KA receptor channel. In contrast to the AMPA receptors, 
editing at the Q/R site of the GRIK2 transcript increases the Ca2+ permeability of the KA receptor [80]. 
Burns and colleagues demonstrated that transcripts encoding the G-protein-coupled 5-HT2C undergo 
editing at sites within the second intracellular loop which results in 3 amino acid changes of isoleucine 
to valine (I/V), asparagine to serine (N/S) and isoleucine to valine (I/V) [81]. RNA editing at these sites 
generates several 5-HT2C isoforms which are expressed at various levels in different brain regions [81]. 
The fully edited 5-HT2C isoform has a reduced affinity for the G-protein PLC which inhibits the 
downstream phosphatidylinositol signal pathway [81]. Therefore, RNA editing regulates the efficacy of 
receptor-G-protein coupling. The Kv1.1 transcript encoded by the voltage gated potassium channel gene 
is edited at a single site and results in an isoleucine-to-valine (I/V) recoding event [82]. The I/V site is 
located in a highly conserved region of the channel pore that is involved in modulating potassium ion 
flow and RNA editing at this site results in the fast inactivation of the Kv1.1 channel [82]. The Gabra-3 
transcript encoding the α3 subunit of the GABAA receptor undergoes site-specific editing, resulting in 
an isoleucine to methionine (I/M) amino acid change [83]. RNA editing at this site increases during 
development and editing levels are inversely related to expression of the α3 subunit containing GABAA 
receptor [84]. 
Overall, the highest levels of site-specific editing events in mammals occur within transcripts 
expressed in the CNS, affecting the functional properties of the proteins. However, the mechanism 
through which ADARs is able to identify a specific adenosine within these transcripts is not yet understood. 
8. RNA Editing in Alu Repeated Sequences 
The continuing development of high throughput sequencing methods has led to major improvements 
in the detection levels of genome-wide editing events. To date it has been estimated that there are over 
one hundred million editing sites in the human genome [85], and the whole transcriptome analysis  
has revealed that A-to-G changes account for greater than 90% of the total mismatches identified in  
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humans [64,86], editing that result in recoding account are rare amongst the total number of editing sites 
identified in the human transcriptome. However the level of editing at site-specific sites is high whereas 
editing of repeat sequences is general low but widespread. 
Alu elements are primate specific non autonomous short interspersed nuclear elements (SINEs) which 
make up approximately 10% of the human genome [87]. The Alu element is approximately 300 bp 
comprising of an A-rich region. Alu repeats are generally clustered in gene rich regions, within UTRs 
and introns [88]. Due to their repetitive nature Alus are capable of forming long intramolecular duplex 
structures through complementary pairing between antisense repeats found within a single pre-mRNA. 
Often two Alu elements are present, adjacent to each other in reverse orientation in the genome which 
are ideal substrates for ADARs. SINE families in mice are not as evolutionary conserved as the primate 
SINE Alu elements so they do not base pair as well. Therefore the editing levels of SINE transcripts in 
mice are lower [65]. 
The functional consequences of editing Alu transcripts in primates remain elusive. The proportion of 
A-to-I editing events that destabilize an A-U pair to an I-U as opposed to stabilizing an A-C pair to an 
I-C is 4:1 respectively [62]. Therefore A-to-I modifications in Alu repeats, regulates the structure and 
stability of the dsRNA formed by Alu elements. 
Alus are mobile elements that retrotranspose through RNA intermediates back into the human genome 
which can result in the disruption of genes [89]. It is possible that the clustering of RNA editing sites 
within individual transcripts could prevent this transposition of Alus [62]. This may also be relevant to 
retroviruses as A-to-I editing by ADARs may protect the host genome from infection by preventing  
their integration. 
Bazak and colleagues found that of the 23,357 human RefSeq genes approximately 14,715 harboured 
editable Alus and 2896 contained Alus in exonic regions [85]. Therefore, it is not surprising that A-to-I 
editing of Alus elements leads to transcript variants in Alu-harboring gene [85,90]. Based on the number 
of edited Alus elements and as there can be up to 11.5 inosines per Alu transcript, A-to-I editing of Alu 
elements undoubtedly is a major contributor to transcritpome diversity [85]. 
9. RNA Editing in miRNA 
The miRNA biogenesis pathway is targeted by ADARs at various stages and this has an impact on 
miRNA processing and miRNA-mediated silencing (For review [91]). A-to-I editing can affect both 
Drosha and Dicer mediated cleavage. For example pri-miR-142, expressed in hematopoietic cells is 
edited by ADAR1p110 and ADAR2 [92]. Yang and colleagues demonstrated that edited pri-miR-142 
could not be processed by Drosha and instead is degraded by Tudor-SN [92]. The pri-miR-151 is also 
subject to RNA editing by both isoforms of ADAR1. However, editing of pri-miR-151 inhibits cleavage 
by Dicer and accumulation of edited pre-miR-151 RNAs therefore suppressing the expression of mature 
miR-151 [93]. 
A-to-I editing by ADARs also affects miRNA-induced silencing complex (miRISC) assembly, 
antagonizing miRNA-mediated gene silencing. For instance, the Epstein Barr virus encoded  
pri-miRBART6 is edited by ADAR1 and this reduces the loading efficiency of miR-BART6 into 
miRISC which in turn reduces the silencing of its target mRNA [94]. 
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The target specificity of mature miRNAs can also be regulated by A-to-I editing. The miR-376 is 
edited by ADAR2 within its “seed” sequence (+4 site), an essential region for RNA duplex formation 
with the complementary target mRNA [95]. Kawahara and colleagues demonstrated that A-to-I editing 
of pri-miR-376 results in the redirection of its silencing effects to a different set of target mRNAs. 
Additionally, ADARs can regulate miRNA processing in an editing-independent manner as the catalytically 
inactive ADAR2 mutant inhibits Drosha processing of pri-miR-376a2 through RNA-binding [96]. Ota 
and colleagues revealed that ADAR1 forms a heterodimer complex with Dicer to promote both the 
cleavage of pre-miRNA by Dicer and the 52 subsequent miRISC mediated gene-silencing events [97]. 
However, this complex has no A-to-I editing activity and, therefore, is another RNA editing-independent 
role of ADAR1 in the RNAi pathway. Together these results demonstrate that the RNA editing and 
RNAi pathways are antagonistic as they compete for similar dsRNA substrates. 
10. ADARs and the Innate Immune Response 
The innateimmune system is the first line response to a pathogenic infection and mounts the rapid 
activation of the initial defense response (For review [98]). The early detection of threat by the cell 
involves the recognition of pathogen associated molecular patterns (PAMPs), which are unique to the 
invading pathogen. These PAMPs are “sensed” as foreign by the host’s specific pattern recognition 
receptors (PRRs). Upon identification of a threat, these cellular detectors recruit specific adaptors which 
activate various signaling pathways to propagate defense signals downstream, ultimately triggering the 
appropriate immune responses in the form of type I IFNs, pro-inflammatory cytokines and chemokines 
(Figure 3). PRRs are classified by their localization within the cell and by the specific type of ligands. 
Three classes of PRRs that detect viral RNA have been discovered: the Toll like receptors (TLRs), the 
retinoic acid-inducible gene-I (RIG-I) like receptors (RLRs), and the nucleotide-binding oligomerization 
domain (NOD)-like receptors (NLRs). The RLRs, retinoic acid inducible gene I (RIG-I) and melanoma 
differentiation-associated gene 5 (MDA5), are located in the cytoplasm. They are both IFN-inducible 
DExD/H box RNA helicases with an RNA binding helicase domain at the C-terminus and two caspase 
activation and recruitment domains (CARDs) at the N-terinmus [99,100]. Activation of RIG-I and 
MDA5 results in the recruitment of the mitochondrial antiviral signaling protein (MAVS) via CARD 
domain interactions. This leads to the translocation of the transcription factors IRF3 and NF-κB and the 
induction of type I IFN and pro-inflammatory cytokines respectively. IRF3 is essential for the 
transcription of type I IFNs in response to viral infection [101]. 
A number of studies have demonstrated the involvement of the ADAR proteins and A-to-I editing 
during viral infection [102–105]. As the majority of viruses replicate within the cytoplasm, they are 
edited by the IFN-inducible isoform of ADAR1, whereas viruses that replicate in the nucleus can be 
edited by either ADAR1p110 or ADAR2 [106]. Depending on the type of virus, the biological 
consequences of A-to-I editing of viral RNA can be either antiviral or proviral [106]. 
Viral dsRNA can be generated from viruses as a result of their genome (dsRNA viruses); hairpin 
secondary structures (viral mRNA), viral transcription (DNA viruses), and viral replication (ssRNA 
viruses). In the last decade many cellular dsRNAs have been found which are derive from different 
processes, such as bidirectional transcription, as well as from repetitive sequences that, when transcribed, 
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can create a source of dsRNA. Therefore, the innate immune system must recognize some molecular 
features to distinguish endogenous dsRNA from viral dsRNA. 
 
Figure 3. Intracellular detection of viral RNA by PRRs and activation of the innate immune 
response. The three classes of PRRs responsible for detection of viral RNA are the TLRs, 
the RLRs, and the NLRs. In the endosome viral ssRNA is detected by TLR7 whereas viral 
dsRNA is recognized by TLR3. TLR7 recruits the signaling adaptor MyD88 whereas TLR3 
associates TRIF. MyD88 elicits the production of type I IFNs through the direct activation 
of IRF7. TRIF activates the TRAF family member-associated TANK and IKKε both of 
which undergo phosphorylation to activate both IRF3 and IRF7. Both IRF3 and IRF7 form 
homodimers which translocate to the nucleus leading to the induction of type I IFN. At the 
same time, both TRIF and MyD88 activate IKK. The IKK complex triggers the release and 
translocation of NF-κB to the nucleus leading to the production of pro-inflammatory 
cytokines. In the cytoplasm, short dsRNA with 5'triphospahte ends is detected by RIG-I and 
long dsRNA is sensed by MDA5. Activation of RIG-I and MDA5 results in the recruitment 
of MAVS via CARD domain interactions. MAVS dependent signaling causes the 
translocation of the transcription factors IRF3 and NF-κB for the induction of type I IFN and 
pro-inflammatory cytokines respectively. The inflammasome is activated by dsRNA via 
NALP3-dependent signaling pathway. NALP3 together with ASC recruit pro-caspase-1 
which in turn undergoes auto-cleavage to produce caspase-1. Activation of caspase-1 is 
required for the cleavage of pro-IL-1β and pro-IL-18, and subsequent secretion of the 
proinflammatory cytokines IL-1β and IL-18, respectively. ADAR1p150 edits dsRNA within 
the cytoplasm and is induced by IFN. 
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Investigations into the biological role of ADAR1 have found that it is a negative regulator of the type 
I IFN response. The Adar1 null mouse have defects in hematopoiesis and liver disintegration as well as 
elevated levels of type I IFN and widespread apoptosis [107–109]. Mouse embryonic fibroblasts (MEFs) 
deficient in ADAR1p150 are highly susceptible to infection and have enhanced viral induced 
cytotoxicity effects [105], implicating ADAR1 as being involved in type I IFN response. 
The Adar1 null mice are dead by stage E12.5 and for over 10 years investigators endeavored to 
elucidate what caused this early lethality [66]. They presumed that these mutant mice lacked an essential 
editing event that would be analogous to ADAR2 editing the Q/R site of GRIA2. A major breakthrough 
was achieved by taking a genetic approach and generating a double mutant with Adar1 [66]. When Adar1 
heterozygous mice were crossed with mice that were homozygous for Mavs, the embryos that were 
double-homozygous survived to birth. The Adar1 mutant embryos had a heightened IFN response 
whereas the double mutants had a response that was similar to their Mavs parents. This places Adar1 
upstream of RIG-I and MDA5 in the innate immune pathway. As MEFs from Adar1 were not viable, 
MEFs were generated from embryos that were Adar1:p53 double mutants. When these MEFs were 
stressed they had a heightened immune response however the addition of inosine containing dsRNA 
alleviated the heightened immune response [66,67]. The explanation for these results is that the cell uses 
inosine to help discriminate between self and non-self dsRNA. If inosine is present in dsRNA it binds  
to -RLRs and prevents activation of the innate immune response. However, if no inosine is present, then 
the cell recognizes the dsRNA as being of viral origin and mounts a type 1 IFN response. 
11. ADARs in Human Disease 
Aicardi-Goutiéres syndrome (AGS) is an autoimmune disorder where patients develop severe 
inflammatory encephalopathy due to chronic activation of the type I IFN [110] (Table 1). AGS patients 
present with symptoms that are similar to an acquired infection. However, there is no infection and 
mutations in genes involved in the regulation of nucleic acid metabolism have been identified in patients 
with this disorder [111]. Therefore, the proposed mechanism of disease pathogenesis is thought to be the 
aberrant activation of the innate immune response caused by the intracellular accumulation of nucleic 
acids [112]. Mutations in ADAR1 have been identified in a subset of patients with AGS [113] and these 
mutations have been shown to reduce the levels of RNA editing. There is a greater reduction in editing 
when these mutations occur in the IFN-inducible ADAR1p150 isoform compared to the constitutively 
expressed ADAR1p110 isoform [66]. This explains the observation that, in some patients with an ADAR1 
mutation, AGS occurs after a viral infection when the ADAR1p150 isoform would be expressed [114]. 
Mutation in other genes also cause AGS with elevated IFN levels and these are; TREX1, SAMHD1, 
RNASEH2A, RNASEH2B, RNASEH2C, and IFIH1(MDA5) (for review [115]). 
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Table 1. List of diseases associated with human ADARs. 
Disease Edited transcripts ADAR Reference 
Prostate cancer PRUNE2/PCA3 ADAR1/ADAR2 [127] 
Hepatocellular carcinoma (HCC) AZIN1 ADAR1 [128] 
 FLNB ADAR1 [130] 
 COPA ADAR2 [130] 
 pre-miR-214 ADAR2 [131] 
Chronic myeloid leukemia (CML) PU.1 (Spi1) ADAR1 [132] 
Glioblastoma (GBM) CDC14B ADAR2 [135] 
 pri-miR-221/222 ADAR2 [139] 
 Pri-miR-21 ADAR2 [139] 
 miR-376a-5p ADAR2 [140] 
 GRIA2 ADAR2 [141] 
Aicardi-Goutiéres Syndrome (AGS) ? ADAR1 [113] 
Dyschromatosis Symmetrica Hereditaria (DSH) ? ADAR1 [116] 
Amyotrophic lateral Sclerosis (ALS) GRIA2 ADAR2 [122] 
12. Dyschromatosis Symmetrica Hereditaria (DSH) 
DSH is an autosomal dominant disorder characterized by hypopigmented and hyperpigmented 
macules localized on the back of the hands and feet in addition to small freckle-like hyperpigmented 
macules on the face [116,117]. The skin lesions usually appear during infancy and generally stop 
spreading before adolescence, lasting the patient’s lifetime [118]. 
Single-strand conformational polymorphism analysis (SSCP) of the candidate genes within this locus 
revealed that each of the patients were heterozygous for mutations in the gene encoding ADAR1 [119]. 
After this first report showing that ADAR1 was the causative gene of DSH, more than 130 mutations in 
the ADAR1 gene have been identified in DSH patients. The mutations include: missense, non-sense, 
frameshift insertions, frameshift deletions, and splice-site. They are not confined to certain hotspots 
within ADAR1; rather, they are spread along the gene. Patients with DSH also have an increased 
expression in IFN transcripts, however, the level is not as high as observed in AGS patients [113]. 
13. Amyotrophic Lateral Sclerosis (ALS) 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that is characterized 
by the selective death of motor neurons. ALS is a fatal disease with a survival rate of less than five years 
subsequent to diagnosis and patients usually die as a result of respiratory failure. Mutations in the 
superoxide dismutase gene (SOD1) have been associated with approximately 20% of the familial cases 
of ALS [120]. However, less than 10% of ALS cases are inherited and the majority of patients develop 
the disease sporadically. Sporadic ALS is characterized by the presence of TAR-DNA binding protein 
(TDP-43)-containing cytoplasmic inclusions in the spinal motor neurons however its pathogenesis 
remains unknown [121]. 
Kawahara and colleagues analyzed the editing levels at the GRIA2 Q/R site in individual motor 
neurons of patients with sporadic ALS, and they observed a significant decrease in the editing levels of 
the Q/R site in GRIA2 transcript when compared to controls [122]. As ADAR2 is the enzyme responsible 
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for editing the Q/R sites in GRIA2 transcripts, these results suggested that defective ADAR2 activity 
could be the causal mechanism of the editing deficiency observed in patients with ALS. Later, a 
conditional transgenic mouse model was generated in which there was loss of Adar2 in motor neurons 
(AR2 mouse model) [123]. These mice exhibited defects in motor function due to the death of Adar2-
deficient motor neurons in the spinal cord. The specific expression of ADAR2 in the AR2 mice 
successfully prevented motor neuron death and rescued motor neuron function [124]. 
14. A-to-I Editing in Cancer 
Consistent with the essential roles played by ADARs in vivo, it is likely that uncontrolled nucleotide 
changes mediated by these enzymes could predispose cells to developmental defects and potential 
oncogenic outcomes. Using both bioinformatics and experimental approaches, it has been found that the 
A-to-I editing pattern is significantly modified in cancers compared to normal tissues [125], with some 
cancers having over-editing and others down-editing events [126]. Here, we discuss some studies of the 
emerging roles of A-I editing in cancer biology (Table 1). 
15. Prostate Cancer 
Prostate cancer antigen 3 (PCA3) is the most specific prostate cancer biomarker and urinary PCA3 
testing has the potential to significantly decrease the number of unnecessary prostate biopsies. However 
PCA3 function remains unknown. PCA3 is an antisense intronic long noncoding (lnc)RNA with the 
potential to base-pair with the sense PRUNE2 transcript. PCA3 expression controls PRUNE2 levels via 
a unique regulatory mechanism involving the formation of a PRUNE2/PCA3 dsRNA that is edited by 
ADARs [127]. PRUNE2 and PCA3 elicited opposite effects on tumor growth in immunodeficient tumor-
bearing mice. Co-regulation of PRUNE2/PCA3 RNA editing was also confirmed in human prostate 
cancer specimens. These results indicated that PCA3 may act as a dominant-negative oncogene, whereas 
PRUNE2 is a possible tumor suppressor gene in human prostate cancer [127]. 
16. Hepatocellular Carcinoma (HCC) 
In hepatocellular carcinoma (HCC) increased editing of the transcript encoding antizyme inhibitor 1 
(AZIN1) by ADAR1 results in increased cell proliferation [128,129]. ADAR2 may also play a role in 
liver tumours as patients with ADAR1 overexpression and down-regulation of ADAR2 have a further 
increase risk of liver cirrhosis and post-operative recurrence with poor prognoses [130]. Hyper-editing 
of FLNB and hypo-editing of COPA transcripts are associated with HCC pathogenesis in a specific HCC 
subset [130]. A study investigated whether ADAR2 may affect miRNA expression in HCC focused on 
a subset of HCC with elevated expression of ADAR2 and found that that ADAR2-mediated editing events 
within pre-miR-214 resulted in decreased levels of mature miR-214 [131]. In this subset of cancer tissues, 
this caused increased protein levels of the novel target of miR-214 which was identified as Rab15. 
17. Chronic Myeloid Leukemia (CML) 
Chronic myeloid leukemia (CML), also known as chronic granulocytic leukemia (CGL), is a 
myeloproliferative disease associated with a characteristic chromosomal translocation; the Philadelphia 
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chromosome. This translocation leads to a fused BCR-ABL protein being able to activate cell 
proliferation through modulation of the cell cycle. Jamieson and colleagues demonstrated that during 
disease progression, there is increased expression of the IFN-γ pathway and among the elevated IFN-
genes is ADAR1 p150 [132]. They found that over-expression of ADAR1 p150 directly correlates with 
the up-regulation of the myeloid transcription factor PU.1. However, ADAR1 knockdown in CML 
progenitors, impaired in vivo the self-renewal capacity of the cells. The transcript encoding PU.1 (Spi1) 
has multiple editing sites; however, the authors did not investigate the mechanism of how the editing 
enzymes modulate the expression of PU.1. Another study of CML with an Adar1 mutant mouse model 
found that ADAR1 deletion reversed leukocytosis and preferentially-depleted primitive Lin-Sca+Kit+ 
(LSK) leukemic cells [133], which would imply that ADAR1 should become a new molecular target for 
CML-directed therapeutics. However, considering the critical role of ADAR1 in the innate immune 
response this approach should proceed with caution [66]. 
18. Glioblastoma 
Several studies have shown a decrease in ADAR2 editing activity in glioblastoma [125,134–137], 
whereas the rescue of ADAR2 in glioblastoma cells inhibited cell proliferation and migration in vitro, 
and more importantly in vivo, with a 100% survival in a mouse model [134,135]. Editing by ADAR2 
inhibits the growth of glioblastoma tumors, indicating the importance of editing of target transcripts for 
glioblastoma regression and possible future therapeutic intervention. The phosphatase CDC14B, which 
acts upstream of the Skp2/p21/p27 pathway, is a critical ADAR2 target involved in glioblastoma  
growth [135]. The decreased ADAR2 activity in glioblastoma causes the loss of the edited miRNA pool 
and the unbalanced expression of several miRNAs with the subsequent up-regulation of several onco-
miRNAs [138,139]. In particular, ADAR2-editing events within precursors of onco-miRs (pri-miR-
221/222 and pri-miR-21) are able to significantly decrease the level of mature miRNAs, leading to a 
significant decrease in cell proliferation and migration [138,139] (Gallo unpublished data). 
Decrease of ADAR2 activity in glioblastoma can also affects miR-376a-5p activity. High-grade 
gliomas accumulate the unedited form of miR-376a-5p, which promotes cell migration and invasion 
while edited miR-376a-5p suppresses these features [140]. A search for specific targets important in 
glioma cell migration found that down-regulation of RAP2A (Ras-related protein Rap-2A) and up-
regulation of AMFR (autocrine motility factor receptor) expression promote in vitro migration and 
invasion of glioma cells [140]. As additional target for glioma progression was identified in the GRIA2 
transcript which is edited by ADAR2 [71], where less editing at the Q/R site enhances glioblastoma 
invasion through activation of the Akt pathway [141]. Overall, these data indicate the essential role of 
ADAR2 editing in glioblastoma, acting on multiple targets (CDC14B, pri-miR-221/222, pri-miR-21, 
miR-376a-5p, GRIA2) that together contribute to varying extents to cancer progression. 
19. Conclusions 
In the last 25 years a lot has been learned about the ADAR family of proteins; however, many 
intriguing questions remain. Despite considerable effort, there is no co-crystal structure of an ADAR 
enzyme bound to dsRNA. How do the enzymes recognize the specific adenosine to edit in transcripts? 
Are there additional co-factors and how do they influence RNA editing? 
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Perhaps the most intriguing question is; are the ADAR proteins heroes or villains? They appear to be 
essential for recoding some neuronal transcripts and mounting an appropriate innate immune response, 
but they also play a significant role in the progression of different types of cancer. Perhaps they play a 
role in both, as in the words of Tennessee Williams, “If I got rid of my demons I’d lose my angels”. 
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